{"id":"pneumococcal-protein-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL4594561","moleculeType":"Vaccine component"},"_dailymed":{"setId":"1158fa93-ef41-4a29-8252-9251f94c53c8","title":"VAXNEUVANCE (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE CRM197 PROTEIN ADSORBED) INJECTION, SUSPENSION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The pneumococcal protein vaccine contains recombinant or purified protein antigens from Streptococcus pneumoniae that trigger both humoral (antibody) and cell-mediated immune responses. By priming the adaptive immune system to recognize pneumococcal proteins, the vaccine enables rapid immune clearance upon exposure to the pathogen, reducing disease incidence and severity.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against pneumococcal protein antigens, preventing infection by Streptococcus pneumoniae.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:21:37.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis)"}]},"trialDetails":[{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":"Acute Otitis Media (AOM)","enrollment":320},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT00339157","phase":"PHASE2, PHASE3","title":"Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-05-11","conditions":"Systemic-Onset Juvenile Idiopathic Arthritis","enrollment":24},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT07059182","phase":"PHASE1","title":"Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-06-11","conditions":"PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media","enrollment":30},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03104075","phase":"PHASE4","title":"Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines","status":"COMPLETED","sponsor":"The Jackson Laboratory","startDate":"2017-04-17","conditions":"Pneumonia, Aging","enrollment":40},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":992},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT05879107","phase":"PHASE3","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-05-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1113},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT05622942","phase":"PHASE1","title":"Clinical Trial of Recombinant Pneumococcal Protein Vaccine","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-03-11","conditions":"Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":60},{"nctId":"NCT05667740","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2023-01-16","conditions":"Pneumococcal Infections","enrollment":118},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06202703","phase":"NA","title":"Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2023-04-15","conditions":"Vaccine-Preventable Diseases","enrollment":5},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT00566098","phase":"PHASE1, PHASE2","title":"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-11","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":26},{"nctId":"NCT05316831","phase":"PHASE4","title":"Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2019-01-01","conditions":"CLL, Vaccine Response","enrollment":77},{"nctId":"NCT04887948","phase":"PHASE3","title":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-20","conditions":"Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection","enrollment":570},{"nctId":"NCT02851056","phase":"EARLY_PHASE1","title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-09-27","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT04087460","phase":"EARLY_PHASE1","title":"Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-10","conditions":"Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":120},{"nctId":"NCT01953510","phase":"PHASE2, PHASE3","title":"Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2013-09-30","conditions":"Pneumococcal Vaccines","enrollment":1400},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT04978038","phase":"PHASE4","title":"Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs","status":"UNKNOWN","sponsor":"Mark Loeb","startDate":"2022-08-01","conditions":"SARS-CoV2 Infection, Coronavirus Infection","enrollment":414},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT02547493","phase":"NA","title":"Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-03-03","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04912297","phase":"","title":"Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10","status":"COMPLETED","sponsor":"Finnish Institute for Health and Welfare","startDate":"2009-11-12","conditions":"Pneumococcal Infections","enrollment":186},{"nctId":"NCT04875819","phase":"PHASE4","title":"Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV","status":"RECRUITING","sponsor":"Thomas Benfield","startDate":"2021-04-28","conditions":"Hiv, Meningococcal Infections, Pneumococcal Infections","enrollment":55},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT03197376","phase":"PHASE3","title":"Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2017-06-21","conditions":"Pneumonia, Pneumococcal","enrollment":2250},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT01545375","phase":"PHASE2","title":"Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05-21","conditions":"Infections, Streptococcal","enrollment":1806},{"nctId":"NCT02943902","phase":"PHASE3","title":"Reduced PCV Dosing Schedules in South African Infants","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2017-01-09","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT00046852","phase":"PHASE1, PHASE2","title":"Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2001-12","conditions":"Infection, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT00834665","phase":"PHASE1","title":"Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-12","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT02308540","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2015-01-12","conditions":"Pneumococcal Disease","enrollment":346},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT02547649","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-08","conditions":"Pneumococcal Infections","enrollment":690},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT01214837","phase":"PHASE3","title":"Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-10","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":751},{"nctId":"NCT01978093","phase":"PHASE3","title":"Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-01","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":600},{"nctId":"NCT00289783","phase":"PHASE3","title":"Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-22","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4441},{"nctId":"NCT00829010","phase":"PHASE3","title":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Infections, Streptococcal","enrollment":489},{"nctId":"NCT00814489","phase":"PHASE1","title":"Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-08","conditions":"Streptococcus Pneumoniae, Haemophilus Influenzae","enrollment":40},{"nctId":"NCT02447432","phase":"PHASE3","title":"A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-11","conditions":"Infections, Streptococcal","enrollment":320},{"nctId":"NCT00993668","phase":"PHASE4","title":"Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2009-09","conditions":"Rheumatoid Arthritis","enrollment":224},{"nctId":"NCT00134719","phase":"PHASE2","title":"Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04-11","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":1104},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT02116998","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2014-09","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":98},{"nctId":"NCT01446926","phase":"PHASE1","title":"Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Pneumonia, Pneumococcal Infections, Streptococcus Pneumoniae Infections","enrollment":280},{"nctId":"NCT00282308","phase":"PHASE2","title":"A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-01-23","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT02892812","phase":"PHASE1","title":"A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2016-09","conditions":"Pneumococcal Infections","enrollment":63},{"nctId":"NCT01654263","phase":"PHASE2","title":"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10-10","conditions":"Pneumococcal Infection","enrollment":884},{"nctId":"NCT00119743","phase":"PHASE3","title":"A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2000-10","conditions":"Hepatitis A","enrollment":5000},{"nctId":"NCT01694329","phase":"","title":"Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada","status":"UNKNOWN","sponsor":"CHU de Quebec-Universite Laval","startDate":"2012-09","conditions":"Acute Upper Respiratory Infection, Acute Lower Respiratory Tract Infection, Otitis Media (OM)","enrollment":1420},{"nctId":"NCT01248988","phase":"","title":"Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Infections, Streptococcal","enrollment":622},{"nctId":"NCT00345683","phase":"PHASE3","title":"Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":4021},{"nctId":"NCT02133469","phase":"NA","title":"PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2012-06","conditions":"Streptococcal Pneumonia, Nasopharyngeal Diseases, Vaccination Adverse Event","enrollment":3281},{"nctId":"NCT01995617","phase":"PHASE1","title":"Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2013-11","conditions":"Streptococcus Pneumoniae","enrollment":90},{"nctId":"NCT00457977","phase":"PHASE3","title":"Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2007-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":181},{"nctId":"NCT00785967","phase":"PHASE3","title":"Immune Responses in Patients Treated With Raltegravir","status":"WITHDRAWN","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2009-01","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00031070","phase":"PHASE2","title":"Increasing HAART-Induced Immune Restoration With Cyclosporine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00133549","phase":"PHASE2","title":"9-valent CRM 197 Pneumococcal","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-11","conditions":"Pneumococcal Infection","enrollment":180},{"nctId":"NCT01444781","phase":"PHASE3","title":"Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Diphtheria, Tetanus, Whooping Cough","enrollment":1106},{"nctId":"NCT01764126","phase":"PHASE1","title":"Pneumococcal Protein Vaccine Safety and Immunogenicity Trial","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2011-09","conditions":"Adverse Effects","enrollment":280},{"nctId":"NCT02123433","phase":"PHASE3","title":"Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults","status":"COMPLETED","sponsor":"University of Siena","startDate":"2011-12","conditions":"HIV Infection, Pneumococcal Infections","enrollment":50},{"nctId":"NCT00050726","phase":"PHASE2","title":"Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-05","conditions":"HIV Infections","enrollment":620},{"nctId":"NCT01767402","phase":"PHASE1","title":"Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10","conditions":"Pneumococcal Disease","enrollment":150},{"nctId":"NCT00323557","phase":"PHASE2","title":"Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06","conditions":"Leukemia","enrollment":39},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT00493324","phase":"PHASE4","title":"Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-07","conditions":"Chronic Plaque Psoriasis","enrollment":43},{"nctId":"NCT01033409","phase":"PHASE1","title":"Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2009-08","conditions":"Pneumonia","enrollment":60},{"nctId":"NCT01444001","phase":"PHASE1","title":"Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Pneumococcal Infections, Pneumococcal Pneumonia","enrollment":63},{"nctId":"NCT01214538","phase":"","title":"Assessment of the Natural Antibody Response to Pneumococcal Surface Proteins During Acute Otitis Media in Children","status":"UNKNOWN","sponsor":"NasVax Ltd","startDate":"2010-10","conditions":"Acute Otitis Media","enrollment":100},{"nctId":"NCT00142389","phase":"PHASE1, PHASE2","title":"Mother's Gift Project","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2004-08","conditions":"Pneumococcal Infections","enrollment":680},{"nctId":"NCT00279734","phase":"PHASE1","title":"Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-08","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT00099658","phase":"NA","title":"Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children","status":"UNKNOWN","sponsor":"CIPRA SA","startDate":"2005-04","conditions":"HIV Infections, Pneumococcal Infections","enrollment":579},{"nctId":"NCT00488826","phase":"PHASE1","title":"Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-10","conditions":"Pneumococcal Infections","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pneumococcal common protein vaccine"],"phase":"marketed","status":"active","brandName":"Pneumococcal protein vaccine","genericName":"Pneumococcal protein vaccine","companyName":"International Centre for Diarrhoeal Disease Research, Bangladesh","companyId":"international-centre-for-diarrhoeal-disease-research-bangladesh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against pneumococcal protein antigens, preventing infection by Streptococcus pneumoniae. Used for Prevention of pneumococcal disease (pneumonia, bacteremia, meningitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}